138 related articles for article (PubMed ID: 35904290)
1. [Possibilities of individual choice of NSAIDs on the example of the oxicam class, taking into account clinical and pharmacological characteristics].
Putilina MV; Teplova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7):36-41. PubMed ID: 35904290
[TBL] [Abstract][Full Text] [Related]
2. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond.
Xu S; Rouzer CA; Marnett LJ
IUBMB Life; 2014 Dec; 66(12):803-11. PubMed ID: 25537198
[TBL] [Abstract][Full Text] [Related]
3. Enzymatic probing of model lipid membranes: phospholipase A2 activity toward monolayers modified by oxicam NSAIDs.
Czapla K; Korchowiec B; Orlof M; Magnieto JR; Rogalska E
J Phys Chem B; 2011 Jul; 115(29):9290-8. PubMed ID: 21682312
[TBL] [Abstract][Full Text] [Related]
4. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions.
Balfour JA; Fitton A; Barradell LB
Drugs; 1996 Apr; 51(4):639-57. PubMed ID: 8706598
[TBL] [Abstract][Full Text] [Related]
5. Photophysical studies of oxicam group of NSAIDs: piroxicam, meloxicam and tenoxicam.
Banerjee R; Chakraborty H; Sarkar M
Spectrochim Acta A Mol Biomol Spectrosc; 2003 Apr; 59(6):1213-22. PubMed ID: 12659890
[TBL] [Abstract][Full Text] [Related]
6. [Cytogenetic studies of human lymphocytes under the influence of oxicams].
Kullich W; Hermann J; Klein G
Z Rheumatol; 1990; 49(2):77-81. PubMed ID: 2349840
[TBL] [Abstract][Full Text] [Related]
7. Modulating Properties of Piroxicam, Meloxicam and Oxicam Analogues against Macrophage-Associated Chemokines in Colorectal Cancer.
Lewandowska P; Szczuka I; Bednarz-Misa I; Szczęśniak-Sięga BM; Neubauer K; Mierzchała-Pasierb M; Zawadzki M; Witkiewicz W; Krzystek-Korpacka M
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885960
[TBL] [Abstract][Full Text] [Related]
8. The reactions of oxicam and sulfoanilide non steroidal anti-inflammatory drugs with hypochlorous acid: determination of the rate constants with an assay based on the competition with para-aminobenzoic acid chlorination and identification of some oxidation products.
Van Antwerpen P; Dubois J; Gelbcke M; Neve J
Free Radic Res; 2004 Mar; 38(3):251-8. PubMed ID: 15129733
[TBL] [Abstract][Full Text] [Related]
9. Differentiating oxicam nonsteroidal anti-inflammatory drugs in phosphoglyceride monolayers.
Czapla K; Korchowiec B; Rogalska E
Langmuir; 2010 Mar; 26(5):3485-92. PubMed ID: 20030324
[TBL] [Abstract][Full Text] [Related]
10. Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network.
Xu S; Hermanson DJ; Banerjee S; Ghebreselasie K; Clayton GM; Garavito RM; Marnett LJ
J Biol Chem; 2014 Mar; 289(10):6799-6808. PubMed ID: 24425867
[TBL] [Abstract][Full Text] [Related]
11. Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail.
Bianchi M; Panerai AE
Pharmacol Res; 2002 Feb; 45(2):101-5. PubMed ID: 11846620
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance.
Engelhardt G; Homma D; Schlegel K; Utzmann R; Schnitzler C
Inflamm Res; 1995 Oct; 44(10):423-33. PubMed ID: 8564518
[TBL] [Abstract][Full Text] [Related]
13. Prevention of cytokine-induced changes in leukocyte adhesion receptors by nonsteroidal antiinflammatory drugs from the oxicam family.
García-Vicuña R; Díaz-González F; González-Alvaro I; del Pozo MA; Mollinedo F; Cabañas C; González-Amaro R; Sánchez-Madrid F
Arthritis Rheum; 1997 Jan; 40(1):143-53. PubMed ID: 9008610
[TBL] [Abstract][Full Text] [Related]
14. Spectroscopic studies of the binding of Cu(II) complexes of oxicam NSAIDs to alternating G-C and homopolymeric G-C sequences.
Chakraborty S; Bose M; Sarkar M
Spectrochim Acta A Mol Biomol Spectrosc; 2014 Mar; 122():690-7. PubMed ID: 24345609
[TBL] [Abstract][Full Text] [Related]
15. Forced and long-term degradation assays of tenoxicam, piroxicam and meloxicam in river water. Degradation products and adsorption to sediment.
Jiménez JJ; Muñoz BE; Sánchez MI; Pardo R
Chemosphere; 2018 Jan; 191():903-910. PubMed ID: 29145135
[TBL] [Abstract][Full Text] [Related]
16. Membrane fusion: a new function of non steroidal anti-inflammatory drugs.
Chakraborty H; Mondal S; Sarkar M
Biophys Chem; 2008 Sep; 137(1):28-34. PubMed ID: 18617319
[TBL] [Abstract][Full Text] [Related]
17. Oxicam-derived non-steroidal anti-inflammatory drugs suppress 1-methyl-4-phenyl pyridinium-induced cell death via repression of endoplasmic reticulum stress response and mitochondrial dysfunction in SH-SY5Y cells.
Omura T; Sasaoka M; Hashimoto G; Imai S; Yamamoto J; Sato Y; Nakagawa S; Yonezawa A; Nakagawa T; Yano I; Tasaki Y; Matsubara K
Biochem Biophys Res Commun; 2018 Sep; 503(4):2963-2969. PubMed ID: 30107908
[TBL] [Abstract][Full Text] [Related]
18. Differential Effect of Oxicam Non-Steroidal Anti-Inflammatory Drugs on Membranes and Their Consequence on Membrane Fusion.
Majumdar A; Kundu D; Sarkar M
J Phys Chem B; 2015 Jul; 119(30):9627-39. PubMed ID: 26147344
[TBL] [Abstract][Full Text] [Related]
19. Interaction of oxicam NSAIDs with DMPC vesicles: differential partitioning of drugs.
Chakraborty H; Roy S; Sarkar M
Chem Phys Lipids; 2005 Dec; 138(1-2):20-8. PubMed ID: 16183046
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
Olkkola KT; Brunetto AV; Mattila MJ
Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
